Elizabeth Anderson
Stock Analyst at Evercore ISI Group
(2.20)
# 2,711
Out of 4,876 analysts
108
Total ratings
46.43%
Success rate
-5.08%
Average return
Main Sectors:
Stocks Rated by Elizabeth Anderson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CAH Cardinal Health | Maintains: Outperform | $175 → $180 | $167.25 | +7.62% | 7 | Jun 12, 2025 | |
| TDOC Teladoc Health | Maintains: In-Line | $8 → $7 | $8.22 | -14.84% | 3 | May 1, 2025 | |
| ALGN Align Technology | Maintains: Outperform | $165 → $200 | $187.46 | +6.69% | 13 | May 1, 2025 | |
| DGX Quest Diagnostics | Maintains: In-Line | $175 → $180 | $177.31 | +1.52% | 3 | Apr 23, 2025 | |
| HCAT Health Catalyst | Downgrades: In-Line | $6 → $4 | $3.81 | +5.12% | 6 | Apr 9, 2025 | |
| FTRE Fortrea Holdings | Maintains: In-Line | $20 → $15 | $5.02 | +198.80% | 7 | Mar 4, 2025 | |
| MCK McKesson | Maintains: Outperform | $650 → $675 | $728.26 | -7.31% | 5 | Feb 6, 2025 | |
| CVS CVS Health | Maintains: Outperform | $60 → $65 | $68.18 | -4.66% | 6 | Jan 27, 2025 | |
| WBA Walgreens Boots Alliance | Maintains: In-Line | $9 → $12 | $11.42 | +5.08% | 13 | Jan 13, 2025 | |
| LH Labcorp Holdings | Upgrades: Outperform | $260 → $265 | $260.31 | +1.80% | 4 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $20 | $15.77 | +26.82% | 7 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $36 | $39.57 | -9.02% | 4 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $270 → $265 | $156.82 | +68.98% | 5 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $34 → $45 | $60.73 | -25.90% | 7 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $7 → $4 | $2.30 | +74.29% | 4 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $23 | $19.56 | +17.59% | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $23 → $20 | $21.84 | -8.42% | 3 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $68 → $26 | $5.65 | +364.60% | 3 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $35 → $15 | $4.13 | +263.20% | 3 | Mar 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $11 | $2.26 | +387.80% | 2 | Jan 4, 2022 |
Cardinal Health
Jun 12, 2025
Maintains: Outperform
Price Target: $175 → $180
Current: $167.25
Upside: +7.62%
Teladoc Health
May 1, 2025
Maintains: In-Line
Price Target: $8 → $7
Current: $8.22
Upside: -14.84%
Align Technology
May 1, 2025
Maintains: Outperform
Price Target: $165 → $200
Current: $187.46
Upside: +6.69%
Quest Diagnostics
Apr 23, 2025
Maintains: In-Line
Price Target: $175 → $180
Current: $177.31
Upside: +1.52%
Health Catalyst
Apr 9, 2025
Downgrades: In-Line
Price Target: $6 → $4
Current: $3.81
Upside: +5.12%
Fortrea Holdings
Mar 4, 2025
Maintains: In-Line
Price Target: $20 → $15
Current: $5.02
Upside: +198.80%
McKesson
Feb 6, 2025
Maintains: Outperform
Price Target: $650 → $675
Current: $728.26
Upside: -7.31%
CVS Health
Jan 27, 2025
Maintains: Outperform
Price Target: $60 → $65
Current: $68.18
Upside: -4.66%
Walgreens Boots Alliance
Jan 13, 2025
Maintains: In-Line
Price Target: $9 → $12
Current: $11.42
Upside: +5.08%
Labcorp Holdings
Jan 7, 2025
Upgrades: Outperform
Price Target: $260 → $265
Current: $260.31
Upside: +1.80%
Jan 7, 2025
Downgrades: In-Line
Price Target: $20
Current: $15.77
Upside: +26.82%
Nov 7, 2024
Maintains: Outperform
Price Target: $32 → $36
Current: $39.57
Upside: -9.02%
Oct 8, 2024
Maintains: Outperform
Price Target: $270 → $265
Current: $156.82
Upside: +68.98%
Oct 8, 2024
Maintains: In-Line
Price Target: $34 → $45
Current: $60.73
Upside: -25.90%
Oct 8, 2024
Maintains: In-Line
Price Target: $7 → $4
Current: $2.30
Upside: +74.29%
Sep 23, 2024
Maintains: Outperform
Price Target: $18 → $23
Current: $19.56
Upside: +17.59%
Jul 9, 2024
Maintains: Outperform
Price Target: $23 → $20
Current: $21.84
Upside: -8.42%
Mar 16, 2022
Maintains: In-Line
Price Target: $68 → $26
Current: $5.65
Upside: +364.60%
Mar 2, 2022
Downgrades: In-Line
Price Target: $35 → $15
Current: $4.13
Upside: +263.20%
Jan 4, 2022
Downgrades: In-Line
Price Target: $11
Current: $2.26
Upside: +387.80%